Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Amortization - GoodwillCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares Issued
Ratios

Legend Biotech (LEGN) Receivables - Other (2019 - 2024)

Legend Biotech filings provide 6 years of Receivables - Other readings, the most recent being $780000.0 for Q4 2024.

  • On a quarterly basis, Receivables - Other fell 1.27% to $780000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $780000.0, a 1.27% decrease, with the full-year FY2024 number at $780000.0, down 1.27% from a year prior.
  • Receivables - Other hit $780000.0 in Q4 2024 for Legend Biotech, down from $790000.0 in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $948000.0 in Q4 2022 to a low of $619000.0 in Q4 2020.
  • Median Receivables - Other over the past 5 years was $785000.0 (2023), compared with a mean of $777000.0.
  • Biggest five-year swings in Receivables - Other: tumbled 40.71% in 2020 and later skyrocketed 35.22% in 2021.
  • Legend Biotech's Receivables - Other stood at $619000.0 in 2020, then skyrocketed by 35.22% to $837000.0 in 2021, then rose by 13.26% to $948000.0 in 2022, then decreased by 16.67% to $790000.0 in 2023, then fell by 1.27% to $780000.0 in 2024.
  • The last three reported values for Receivables - Other were $780000.0 (Q4 2024), $790000.0 (Q4 2023), and $948000.0 (Q4 2022) per Business Quant data.